Summary
Regeneron Pharmaceuticals, Inc. reported strong financial performance for the nine months ended September 30, 2018, with total revenues reaching $4.78 billion, a significant increase from $4.29 billion in the prior year period. Net income also saw a substantial rise to $1.62 billion from $1.02 billion, translating to diluted earnings per share of $14.14, up from $8.84 in the same period last year. This growth was primarily driven by robust net product sales, particularly for EYLEA in the U.S., which increased by $270.7 million to $2.99 billion. Collaboration revenues also contributed positively, with significant growth from the Bayer EYLEA collaboration. The company's balance sheet strengthened, with total assets growing to $10.81 billion, supported by a healthy increase in cash and cash equivalents and marketable securities, indicating strong liquidity. The company also made notable progress on its product pipeline. Key developments include the FDA approval of Libtayo for advanced cutaneous squamous cell carcinoma and expanded indications for Dupixent in asthma. The company is actively investing in its manufacturing capabilities and continues to advance its numerous product candidates across various therapeutic areas, underscoring a strong commitment to future growth and innovation. Despite ongoing patent litigations, particularly concerning Praluent and Dupixent, the financial results demonstrate operational strength and successful commercial execution.
Financial Highlights
42 data points| Revenue | $1.66B |
| R&D Expenses | $557.00M |
| SG&A Expenses | $369.20M |
| Operating Expenses | $1.04B |
| Operating Income | $626.90M |
| Interest Expense | $7.40M |
| Net Income | $594.70M |
| EPS (Basic) | $5.50 |
| EPS (Diluted) | $5.17 |
| Shares Outstanding (Basic) | 108.00M |
| Shares Outstanding (Diluted) | 115.10M |
Key Highlights
- 1Total revenues increased to $4.78 billion for the nine months ended September 30, 2018, up from $4.29 billion in the prior year period.
- 2Net income rose significantly to $1.62 billion, or $14.14 per diluted share, compared to $1.02 billion, or $8.84 per diluted share, in the same period last year.
- 3EYLEA net product sales in the U.S. increased by $270.7 million to $2.99 billion for the nine months ended September 30, 2018.
- 4The Bayer collaboration revenue saw a substantial increase of $134.3 million, reaching $775.2 million for the nine months ended September 30, 2018.
- 5Cash and cash equivalents increased by $275.1 million to $1.09 billion, and marketable securities grew by $1.17 billion to $4.07 billion, indicating strong liquidity.
- 6Significant pipeline progress includes FDA approval of Libtayo for advanced CSCC and expanded indications for Dupixent in asthma.
- 7Operating expenses increased to $2.97 billion from $2.75 billion, largely due to higher R&D and SG&A expenses, reflecting continued investment in growth.